Clinerion partners with the Czech Clinical Research Institute to bring its services to patients...
The Czech Clinical Research Institute (CCRI) will support patients and physicians in the Czech Republic and Slovakia in accessing innovative treatments by expanding Clinerion’s...
Data Collection in Phase II-III Clinical Research – It is Ripe for Disruption?
Current data collection practices in clinical research are facing many challenges. There is a broad recognition that issues prevail with the current clinical research...
The Essential Role of Interactive Response Technology (IRT) in Clinical Trial Supply
Increasingly elaborate international clinical trials are demanding a smarter, streamlined approach from supply partners and better collaboration with sponsors.
In this environment, Interactive Response Technology...
Pfizer unveils new Phase 2 data on 20-valent pneumococcal conjugate vaccine
Pfizer has revealed new Phase 2 data on its 20-valent pneumococcal conjugate vaccine candidate, known as PF-06482077 (20vPnC) Detailing the efficacy...
Biokin Pharmaceutical Selects Cryoport’s Temperature-Controlled Solutions for its Pending Phase I and Phase II...
Biokin Pharmaceutical Co. Ltd. a leading pharmaceutical company with operations in China and U.S., and Cryoport, Inc. , the world's leading temperature-controlled logistics company...
2019 Trends to Watch For in the Global Clinical Trials Sector
The industry’s pledge to improve the clinical trial experience for participants and investigative sites is taking center stage in 2019. Greenphire’s CEO, Jim Murphy,...
Clinerion partners with MEDSOFT on expanding clinical research in Georgia
Clinerion will offer its services to hospitals in Georgia, bringing them access to international clinical studies and the use of Patient Network Explorer for...
Ochsner Health System and Pfizer Partner to Develop Innovative Models for Clinical Trials
Ochsner Health System, Louisiana’s largest non-profit academic healthcare system, and Pfizer Inc have entered into a multi-year strategic alliance to develop innovative models for...
CStone receives CTA approval in China to start Phase I trial for FGFR4 inhibitor...
CStone Pharmaceuticals announced that the National Medical Products Administration (NMPA) recently approved the clinical trial application (CTA) to start a Phase I clinical trial...
Bavarian Nordic Completes Enrollment of First Stage in Chordoma Phase 2 Trial
Bavarian Nordic A/S announced , that the first stage of a Phase 2 study of its novel, targeted cancer immunotherapy candidate, BN-Brachyury in the...
